Free tool
Oncology stocks
We cover 62 companies grouped under the Oncology theme. The median market value in the group is $86.44M. Across the group, the median move over the past trading day is 0.00%. 43% of the 58 with a 200-day average trade above it. Price change over the past year runs from −61.3% to +185.5% across the middle 80 percent of the group, with a median of −5.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
62 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 0I3Q.L | Corcept Therapeutics Incorporated | $123.12 | +0.43% | +234.90% | +74.96% |
| HCM.L | HUTCHMED (China) Limited | 179.00 GBP | +3.17% | −12.25% | −18.08% |
| NANO.PA | Nanobiotix S.A. | 35.74 EUR | +8.43% | +88.11% | +358.21% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.82% | −12.36% | −44.50% |
| 0HFQ.L | AnaptysBio, Inc. | $57.99 | −1.29% | +26.89% | +187.79% |
| PHIL.MI | Philogen S.p.A. | 23.85 EUR | +1.06% | +6.10% | +4.75% |
| EUZ.DE | Eckert & Ziegler SE | 13.18 EUR | −4.56% | −12.19% | −24.60% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $11.20 | +4.38% | +42.55% | +9.60% |
| 0QAV.L | Nanobiotix S.A. | 35.02 EUR | −1.38% | +82.87% | +351.98% |
| 0KCS.L | OPKO Health, Inc. | $1.49 | +0.68% | +14.66% | +5.64% |
| 0IL8.L | Kyntra Bio, Inc. | $7.96 | +1.58% | −11.17% | −28.07% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.04 EUR | +0.97% | −90.91% | −90.91% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.81 EUR | +8.00% | +386.49% | +1198.08% |
| 0LOV.L | Verastem, Inc. | $7.15 | +3.62% | −1.79% | −19.93% |
| AVCT.L | Avacta Group Plc | 69.50 GBP | +0.72% | +20.87% | +26.36% |
| PRTC.L | PureTech Health plc | 121.20 GBP | +0.17% | −2.73% | −4.27% |
| 0XOD.L | UroGen Pharma Ltd. | $46.18 | −1.66% | +104.45% | +136.88% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.57% | −15.34% | −22.50% |
| 0IV3.L | Geron Corporation | $1.53 | −0.97% | +15.53% | +7.77% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +19.01% | +16.21% | +1.19% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +5.42% | −17.21% | −23.46% |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.66% |
| SCLP.L | Scancell Holdings plc | 9.70 GBP | −2.02% | −2.02% | −7.62% |
| HPHA.DE | Heidelberg Pharma AG | 2.52 EUR | −2.70% | +0.80% | −31.15% |
| 0RU5.L | Oncoinvent ASA | 85.40 NOK | 0.00% | +96.77% | +7339.02% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 74.00 PLN | −0.80% | −1.33% | +80.49% |
| 0RDB.L | Oryzon Genomics S.A. | 2.87 EUR | +2.06% | −10.03% | +5.90% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.40 PLN | +22.67% | −32.23% | −36.99% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −79.24% |
| OSE.PA | OSE Immunotherapeutics SA | 3.21 EUR | −0.19% | −39.40% | −47.94% |
| 0QW5.L | Heidelberg Pharma AG | 2.46 EUR | 0.00% | −2.38% | −33.15% |
| 0J4V.L | Heron Therapeutics, Inc. | $0.31 | −3.55% | −76.14% | −78.12% |
| POLB.L | Poolbeg Pharma PLC | 8.60 GBP | +36.51% | +120.51% | +164.62% |
| 0QXX.L | Molecular Partners AG | 3.51 CHF | +2.33% | +3.54% | +17.00% |
| SAR.L | Sareum Holdings plc | 37.00 GBP | +76.19% | +117.65% | +76.19% |
| MAAT.PA | MaaT Pharma SA | 3.04 EUR | +8.96% | −45.52% | −33.91% |
| 0OCQ.L | Transgene SA | 0.81 EUR | −0.25% | −16.36% | −22.31% |
| 0RAD.L | OSE Immunotherapeutics SA | 3.19 EUR | −1.30% | −39.91% | −48.50% |
| CANTA.ST | Cantargia AB (publ) | 1.91 SEK | +3.24% | −53.64% | −27.38% |
| COIL.L | Coiled Therapeutics plc | 9.50 GBP | −9.52% | −20.83% | −26.92% |
| SVE.WA | Synthaverse S.A. | 3.06 PLN | +9.29% | −20.21% | −36.25% |
| MOC.WA | Molecure S.A. | 6.03 PLN | −2.58% | −8.08% | −22.39% |
| NNG.WA | NanoGroup S.A. | 2.38 PLN | −4.80% | −11.19% | −17.36% |
| DEX.ST | Dextech Medical AB | 10.30 SEK | −0.96% | +11.35% | +26.38% |
| ALTME.PA | TME Pharma N.V. | 0.13 EUR | +113.11% | +88.41% | +25.97% |
| ABERA.ST | Abera Bioscience AB | 8.18 SEK | −2.62% | +13.61% | +1.61% |
| B8FK.DE | Biofrontera AG | 2.53 EUR | −0.78% | −0.78% | −3.07% |
| ACTI.ST | Active Biotech AB (publ) | 5.50 SEK | +6.38% | +19.57% | −62.00% |
| CRTX.L | CRISM Therapeutics Corporation | 11.50 GBP | +21.05% | +15.00% | +9.52% |
| 0NWK.L | Valerio Therapeutics Société anonyme | 0.86 EUR | +8.09% | +418.18% | +1279.03% |
| PUR.WA | MultiQure S.A. | 3.05 PLN | +40.23% | −25.43% | −55.05% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | 0.32 EUR | +2.57% | −18.41% | −19.44% |
| CHOSA.ST | Chosa Oncology AB | 0.73 SEK | −14.15% | −20.00% | −9.00% |
| NFX.L | Nuformix plc | 0.16 GBP | +6.71% | −46.10% | +80.68% |
| 0GP7.L | Medivir AB (publ) | 2.03 SEK | +6.77% | +345.66% | +1.60% |
| DBP-B.ST | Double Bond Pharmaceutical International AB (publ) | 0.16 SEK | +30.42% | +16.79% | +11.79% |
| VAL.L | ValiRx plc | 0.16 GBP | +3.33% | −57.53% | −73.04% |
| 0RK9.L | Alligator Bioscience AB (publ) | 0.03 SEK | +10.16% | −90.40% | −99.13% |
| ATORX.ST | Alligator Bioscience AB (publ) | 0.03 SEK | −32.46% | −91.74% | −99.27% |
| PTP.DE | Pentixapharm Holding AG | 1.85 EUR | −5.61% | +20.13% | +5.47% |
| 0GQU.L | Active Biotech AB (publ) | 5.46 SEK | +5.61% | +7801.59% | +7801.59% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.